Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB039A in Advanced Solid Tumors (Phase I/II)
CTR20240621Phase 2Active
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Mar 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MHB039A in Nonhematologic neoplasms, sponsored by Minghui Pharmaceutical, Inc. Primary endpoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Incidence of dose-limiting toxicities (DLTs) and 2 more. Started Mar 2024; status: active.
02
Drugs
MHB039A
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20240621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240621.